Malignant and Benign Diseases of the Eye and Orbit

  • Jason Chan
  • Kavita K. MishraEmail author


This chapter will discuss uveal melanoma, ocular lymphoma, intraocular lymphoma, thyroid ophthalmopathy, and orbital lymphoid hyperplasia (for Retinoblastoma and Rhabdomyosarcoma, see Chap.  41).


Uveal melanoma Orbital lymphoma Intraocular lymphoma Thyroid ophthalmopathy Orbital lymphoid hyperplasia 



We thank Tania Kaprealian MD, Alice Wang-Chesebro MD, and Jeanne Marie Quivey MD, FACR, for their work on the prior edition of this chapter.


  1. Akpek E, et al. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes. Ophthalmology. 1999;106:1805–10.CrossRefGoogle Scholar
  2. Aziz HA, Singh N, Bena J, Wilkinson A, Singh AD. Vision loss following episcleral brachytherapy for uveal melanoma: development of a vision prognostication tool. JAMA ophthalmology. 2016;134(6):615–20.CrossRefGoogle Scholar
  3. Bell D, et al. Choroidal melanoma: natural history and management options. Cancer Control. 2004;11(5):296–303.CrossRefGoogle Scholar
  4. Berenbom A, Davila RM, Lin H-S, et al. Treatment outcomes for primary intraocular lymphoma: implications for external beam radiotherapy. Eye. 2007;21:1198–201.CrossRefGoogle Scholar
  5. Bhatia S, et al. Curative radiotherapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys. 2002;54:818–21.CrossRefGoogle Scholar
  6. Bolek T, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys. 1999;44:31–6.CrossRefGoogle Scholar
  7. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for graves ophthalmopathy. Ophthalmology. 2008;115:398–409.CrossRefGoogle Scholar
  8. Chan C, Wallace D. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11(5):285–95.CrossRefGoogle Scholar
  9. Chang MY, McCannel TA. Local treatment failure after globe- conserving therapy for choroidal melanoma. Br J Ophthalmol. 2013;97:804–11.CrossRefGoogle Scholar
  10. Char D, et al. Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology. 1988;95:625–30.CrossRefGoogle Scholar
  11. Char D, Quivey J, et al. Helium ions versus I-125 brachytherapy in management of uveal melanoma. A prospective, dynamically balanced trial. Ophthalmology. 1993;100:1547–54.CrossRefGoogle Scholar
  12. Choudhary MM, Gupta A, Bena J, Emch T, Singh AD. Hepatic ultrasonography for surveillance in pts with uveal melanoma. JAMA Ophthalmol. 2016;134(2):174–80.CrossRefGoogle Scholar
  13. COMS. Mortality in pts with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol. 1997;115:886.CrossRefGoogle Scholar
  14. COMS. The COMS randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report no 24. Am J Ophthalmol. 2004;138(6):936.CrossRefGoogle Scholar
  15. COMS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report no. 28. Arch Ophthalmol. 2006;124:1684.CrossRefGoogle Scholar
  16. Daftari I, et al. Newer radiation modalities for choroidal tumors. Int Ophthal Clin. 2006;46:69.CrossRefGoogle Scholar
  17. Diener-West M, et al. Screening for metastasis from choroidal melanoma: the COMS group report 23. J Clin Oncol. 2004;22:2438–44.CrossRefGoogle Scholar
  18. Diener-West M, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: COMS report no. 26. Arch Ophthalmol. 2005;123(12):1639.CrossRefGoogle Scholar
  19. Egger E, et al. Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001;51:138.CrossRefGoogle Scholar
  20. Esik O, et al. Retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin’s lymphomas. Radiother Oncol. 1996;38:13–8.CrossRefGoogle Scholar
  21. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy× 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86(5):930–5.CrossRefGoogle Scholar
  22. Force, Task, and ABS–OOTF Committee. The American brachytherapy society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.CrossRefGoogle Scholar
  23. Gragoudas ES. Proton beam irradiation of uveal melanomas: the first 30 years. Invest Ophthalmol Vis Sci. 2006;47:4666–73.CrossRefGoogle Scholar
  24. Gragoudas ES, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol. 2000;118:773.CrossRefGoogle Scholar
  25. Grimm SA, et al. Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol. 2007;18:1851–5.CrossRefGoogle Scholar
  26. Hoffman PM, et al. Intraocular lymphoma: a series of 14 pts with clinicopathological features and treatment outcomes. Eye. 2003;17:513–21.CrossRefGoogle Scholar
  27. Hrbacek J, Mishra KK, Kacperek A, et al. Practice patterns analysis of ocular proton therapy centers: the international OPTIC survey. Int J Radiat Oncol Biol Phys. 2016;95:336–43.CrossRefGoogle Scholar
  28. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A. Modern radiation therapy for nodal non-hodgkin lymphoma—target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.CrossRefGoogle Scholar
  29. Jeganathan V, Swetha E, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. Int J Radiat Oncol Biol Phys. 2011;79(3):650–9.CrossRefGoogle Scholar
  30. Kath R, et al. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219–23.CrossRefGoogle Scholar
  31. Kujala E, et al. Very long term prognosis of pts with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–9.CrossRefGoogle Scholar
  32. Lanciano R, et al. The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys. 1990;18:407.CrossRefGoogle Scholar
  33. Lane AM, Kim IK, Gragoudas ES. Long-term risk of melanoma-related mortality for pts with uveal melanoma treated with proton beam therapy. JAMA Ophthalmol. 2015;133(7):792–6.CrossRefGoogle Scholar
  34. Le Q, et al. Primary radiotherapy for localized orbital malt lymphoma. Int J Radiat Oncol Biol Phys. 2002;52:657–63.CrossRefGoogle Scholar
  35. Marucci L, Lane AM, Li W, et al. Conservation treatment of the eye: conformal proton reirradiation for recurrent uveal melanoma. Int J Radiat Oncol Biol Phys. 2006;64:1018–22.CrossRefGoogle Scholar
  36. Mishra KK, Quivey JM, Daftari IK, Weinberg V, Cole T, Patel K, Castro JR, Phillips TL, Char DH. Long-term results of the UCSF-LBNL randomized trial: charged particle with helium ion versus iodine-125 plaque therapy for choroidal and ciliary body melanoma. Int J Radiat Oncol Biol Phys. 2015a;92(2):376–83.CrossRefGoogle Scholar
  37. Muller K, Naus N, Nowak PJCM, Schmitz PIM, De Pan C, Van Santen CA, et al. Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. Radiother Oncol. 2012;102:219–24.CrossRefGoogle Scholar
  38. Nag S, et al. The American brachytherapy society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56:544.CrossRefGoogle Scholar
  39. Nathan P, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2404–12.CrossRefGoogle Scholar
  40. Nguyen LN, Ang K. The orbit. In: Cox J, Ang K, editors. Radiation oncology. 8th ed. St. Louis: Mosby; 2003. p. 282–92.Google Scholar
  41. Pelloski CE, et al. Clinical stage IEA-IIEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiother Oncol. 2001;59:145–51.CrossRefGoogle Scholar
  42. Peterson IA, et al. Prognostic factors in the radiotherapy of graves’ ophthalmopathy. Int J Radiat Oncol Biol Phys. 1990;19:259–64.CrossRefGoogle Scholar
  43. Peterson K, et al. The clinical spectrum of ocular lymphoma. Cancer. 1993;72:843–9.CrossRefGoogle Scholar
  44. Pfeffer MR, Rabin T, Tsvang L, et al. Orbital lymphoma: is it necessary to treat the entire orbit? Int J Radiat Oncol Biol Phys. 2004;60:527–30.CrossRefGoogle Scholar
  45. Prabhu RS, Kandula S, Liebman L, Wojno TH, Hayek B, Hall WA, Shu HK, Crocker I.Association of clinical response and long-term outcome among patients with biopsied orbital pseudotumor receiving modern radiation therapy. Int J Radiat Oncol Biol Phys. 2013;85(3):643–9.CrossRefGoogle Scholar
  46. Prummel M, et al. Randomized double-blind trial of prednisone versus radiotherapy in graves’ ophthalmopathy. Lancet. 1993;342:949–54.CrossRefGoogle Scholar
  47. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in pts with mild graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15–20.CrossRefGoogle Scholar
  48. Quivey J, Char D, et al. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26(4):613–8.CrossRefGoogle Scholar
  49. Rosenthal S. Benign disease. In: Leibel SA, Phillips TL, editors. Textbook of radiation oncology. 2nd ed. Philadelphia: Saunders; 2004. p. 1525–43.Google Scholar
  50. Shields C, Shields J. Diagnosis and management of retinoblastoma. Cancer Control. 2004;11(5):317–27.CrossRefGoogle Scholar
  51. Shields CL, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219–28.CrossRefGoogle Scholar
  52. Shields J, et al. Survey of 1264 pts with orbital tumors and simulating lesions. Ophthalmology. 2004;111:997–1008.CrossRefGoogle Scholar
  53. Stafford SL, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001;59:139–44.CrossRefGoogle Scholar
  54. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE. Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47–54.CrossRefGoogle Scholar
  55. Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone. Leuk Lymphoma. 2014;55(4):795–801.CrossRefGoogle Scholar
  56. Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol. 2016;28(8):e17–27.CrossRefGoogle Scholar
  57. Weber DC, Bogner J, Verwey J, et al. Proton beam radiotherapy versus fractionated stereotactic radiotherapy for uveal melanomas: a comparative study. Int J Radiat Oncol Biol Phys. 2005;63:373–84.CrossRefGoogle Scholar
  58. Woolf DK, et al. Outcomes of primary lymphoma of the ocular adnexa (orbital lymphoma) treated with radiotherapy. Clin Oncol. 2015;27(3):153–9.CrossRefGoogle Scholar
  59. Zytkovicz A, et al. Peripheral dose in ocular treatments with cyberknife and gamma knife radiosurgery compared to proton radiotherapy. Phys Med Biol. 2007;52(19):5957.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations